Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2012 Nov 13;22(5):569-70. doi: 10.1016/j.ccr.2012.10.016.

Epigenetic therapy leaps ahead with specific targeting of EZH2.

Author information

1
Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA. amm2014@med.cornell.edu

Abstract

The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in B cell lymphomas. Two recent reports describe the development of highly selective EZH2 inhibitors and reveal mutant EZH2 as playing an essential role in maintaining lymphoma proliferation. EZH2 inhibitors are thus a promising new targeted therapy for lymphoma.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center